Glycodelin expression associates with differential tumour phenotype and outcome in sporadic and familial non-BRCA1/2 breast cancer patients

Breast Cancer Research and Treatment

Volumn 128, Issue 1, 2011, Pages 85-95

  Hautala, Laura C ^a   Greco, Dario ^a   Koistinen, Riitta ^a   Heikkinen, Tuomas ^a   Heikkilä, Päivi ^a   Aittomäki, Kristiina ^a   Blomqvist, Carl ^a   Koistinen, Hannu ^a   Nevanlinna, Heli ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Breast cancer; Familial breast cancer; Glycodelin; Non BRCA1 2; PAEP

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLACENTA PROTEIN 14;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILIAL CANCER; FAMILY HISTORY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PAEP GENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDIES; GLYCOPROTEINS; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PHENOTYPE; PREGNANCY PROTEINS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 79959226099     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1065-y     Document Type: Article

References (41)

1. M Seppälä RN Taylor H Koistinen, et al. 2002 Glycodelin: a major lipocalin protein of the reproductive axis with diverse actions in cell recognition and differentiation Endocr Rev 23 401 430 12202458 10.1210/er.2001-0026 (Pubitemid 34925639)
2. HR Morris A Dell RL Easton, et al. 1996 Gender-specific glycosylation of human glycodelin affects its contraceptive activity J Biol Chem 271 32159 32167 8943270 10.1074/jbc.271.50.32159 1:CAS:528:DyaK2sXit1SjtA%3D%3D (Pubitemid 26422248)
3. WS Yeung KF Lee R Koistinen, et al. 2009 Effects of glycodelins on functional competence of spermatozoa J Reprod Immunol 83 26 30 19857900 10.1016/j.jri.2009.04.012 1:CAS:528:DC%2BD1MXhsVyntr3O
4. A Alok AA Karande 2009 The role of glycodelin as an immune-modulating agent at the feto-maternal interface J Reprod Immunol 83 124 127 19896207 10.1016/j.jri.2009.06.261 1:CAS:528:DC%2BD1MXhsVynsbfI
5. M Seppälä H Koistinen R Koistinen, et al. 2009 Glycodelin in reproductive endocrinology and hormone-related cancer Eur J Endocrinol 160 121 133 19039086 10.1530/EJE-08-0756
6. M Kamäräinen M Seppälä I Virtanen, et al. 1997 Expression of glycodelin in MCF-7 breast cancer cells induces differentiation into organized acinar epithelium Lab Invest 77 565 573 9426393 (Pubitemid 28018776)
7. LC Hautala R Koistinen M Seppälä, et al. 2008 Glycodelin reduces breast cancer xenograft growth in vivo Int J Cancer 123 2279 2284 18720404 10.1002/ijc.23773 1:CAS:528:DC%2BD1cXhtleiurjE
8. H Koistinen M Seppälä B Nagy, et al. 2005 Glycodelin reduces carcinoma-associated gene expression in endometrial adenocarcinoma cells Am J Obstet Gynecol 193 1955 1960 16325596 10.1016/j.ajog.2005.05.073 1:CAS:528:DC%2BD2MXht1Olt7nM (Pubitemid 41737618)
9. H Uchida T Maruyama T Nagashima, et al. 2005 Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin Endocrinology 146 5365 5373 16123169 10.1210/en.2005-0359 1:CAS:528:DC%2BD2MXht1OgurrL (Pubitemid 41653050)
10. K Ohta T Maruyama H Uchida, et al. 2008 Glycodelin blocks progression to S phase and inhibits cell growth: a possible progesterone-induced regulator for endometrial epithelial cell growth gycodelin inhibits G1/S progression Mol Hum Reprod 14 17 22 18178606 10.1093/molehr/gam081 1:CAS:528:DC%2BD1cXlsV2nurw%3D (Pubitemid 351267222)
11. H Koistinen LC Hautala M Seppälä, et al. 2009 The role of glycodelin in cell differentiation and tumor growth Scand J Clin Lab Invest 69 452 459 19551557 10.1080/00365510903056023 1:CAS:528:DC%2BD1MXnvVOru7w%3D
12. E Mandelin H Lassus M Seppälä, et al. 2003 Glycodelin in ovarian serous carcinoma: association with differentiation and survival Cancer Res 63 6258 6264 14559812 1:CAS:528:DC%2BD3sXotV2jurY%3D (Pubitemid 37255172)
13. M Kämäräinen M Halttunen R Koistinen, et al. 1999 Expression of glycodelin in human breast and breast cancer Int J Cancer 83 738 742 10597188 10.1002/(SICI)1097-0215(19991210)83:6<738::AID-IJC7>3.0.CO;2- F
14. U Jeschke I Mylonas C Kunert-Keil, et al. 2005 Expression of glycodelin protein and mRNA in human ductal breast cancer carcinoma in situ, invasive ductal carcinomas, their lymph node and distant metastases, and ductal carcinomas with recurrence Oncol Rep 13 413 419 15706409 1:CAS:528: DC%2BD2MXisVSnu7Y%3D
15. C Scholz B Toth E Barthell, et al. 2009 Immunohistochemical expression of glycodelin in breast cancer correlates with estrogen-receptor alpha and progesterone-receptor A positivity Histol Histopathol 24 467 471 19224449 1:CAS:528:DC%2BD1MXltFCntr8%3D
16. K Syrjäkoski P Vahteristo H Eerola, et al. 2000 Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients J Natl Cancer Inst 92 1529 1531 10995809 10.1093/jnci/92.18.1529
17. O Kilpivaara J Bartkova H Eerola, et al. 2005 Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients Int J Cancer 113 575 580 15472904 10.1002/ijc.20638 1:CAS:528:DC%2BD2MXms1Gi (Pubitemid 40038733)
18. H Eerola C Blomqvist E Pukkala, et al. 2000 Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 36 1143 1148 10854948 10.1016/S0959-8049(00)00093-9 1:STN:280:DC%2BD3czhsVWqsA%3D%3D (Pubitemid 30330913)
19. P Vehmanen LS Friedman H Eerola, et al. 1997 Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes Hum Mol Genet 6 2309 2315 9361038 10.1093/hmg/6.13.2309 1:CAS:528:DyaK2sXotFWisrg%3D (Pubitemid 27501084)
20. P Vahteristo H Eerola A Tamminen, et al. 2001 A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families Br J Cancer 84 704 708 11237395 10.1054/bjoc.2000.1626 1:CAS:528:DC%2BD3MXisVeru7o%3D (Pubitemid 32239008)
21. P Vahteristo J Bartkova H Eerola, et al. 2002 A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer Am J Hum Genet 71 432 438 12094328 10.1086/341943 1:CAS:528:DC%2BD38XlvV2qur8%3D (Pubitemid 34800260)
22. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 1757079 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D
23. J Tommiska H Eerola M Heinonen, et al. 2005 Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival Clin Cancer Res 11 5098 5103 16033823 10.1158/1078-0432.CCR-05-0173 1:CAS:528:DC%2BD2MXmt12qtLk%3D (Pubitemid 41003693)
24. K Aaltonen C Blomqvist RM Amini, et al. 2008 Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers Clin Cancer Res 14 1976 1983 18381935 10.1158/1078-0432.CCR-07-4100 1:CAS:528:DC%2BD1cXkt1akur4%3D (Pubitemid 351551106)
25. C Ahlin K Aaltonen RM Amini, et al. 2007 Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 51 491 498 17711446 10.1111/j.1365-2559.2007.02798.x 1:STN:280:DC%2BD2srmtFWhug%3D%3D (Pubitemid 47437828)
26. T Heikkinen H Kärkkäinen K Aaltonen, et al. 2009 The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype Clin Cancer Res 15 3214 3222 19383810 10.1158/1078-0432.CCR-08- 3128 1:CAS:528:DC%2BD1MXltFOrurk%3D
27. Blows FM, Driver KE, Schmidt MK et al (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7:e1000279
28. LM McShane DG Altman W Sauerbrei, et al. 2005 Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 9067 9072 16172462 10.1200/JCO.2004.01.0454
29. H Eerola P Heikkilä A Tamminen, et al. 2005 Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families Breast Cancer Res 7 R465 R469 15987451 10.1186/bcr1025 1:CAS:528:DC%2BD2MXls1GjtLk%3D
30. RC Gentleman VJ Carey DM Bates, et al. 2004 Bioconductor: open software development for computational biology and bioinformatics Genome Biol 5 R80 15461798 10.1186/gb-2004-5-10-r80
31. P Du WA Kibbe SM Lin 2008 Lumi: a pipeline for processing Illumina microarray Bioinformatics 24 1547 1548 18467348 10.1093/bioinformatics/btn224 1:CAS:528:DC%2BD1cXnvV2rtLg%3D (Pubitemid 351911712)
32. BM Bolstad RA Irizarry M Astrand, et al. 2003 A comparison of normalization methods for high density oligonucleotide array data based on variance and bias Bioinformatics 19 185 193 12538238 10.1093/bioinformatics/19. 2.185 1:CAS:528:DC%2BD3sXitlCnsL4%3D (Pubitemid 36181903)
33. T Tatusova 2010 Genomic databases and resources at the national center for biotechnology information Methods Mol Biol 609 17 44 20221911 10.1007/978-1-60327-241-4-2 1:CAS:528:DC%2BC3cXnvFWmt7c%3D
34. DW Huang BT Sherman RA Lempicki 2009 Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Nat Protoc 4 44 57 10.1038/nprot.2008.211 1:CAS:528:DC%2BD1cXhsFCkurnI
35. K Aaltonen RM Amini G Landberg, et al. 2009 Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer Breast Cancer Res Treat 113 75 82 18240019 10.1007/s10549-008-9908-5 1:CAS:528:DC%2BD1cXhsFWrs7bL
36. Ren S, Liu S, Howell PM Jr et al (2009) Functional characterization of the progestagen-associated endometrial protein gene in human melanoma. J Cell Mol Med. doi: 10.1111/j.1582-4934.2009.00922.x
37. J Palacios MJ Robles-Frias MA Castilla, et al. 2008 The molecular pathology of hereditary breast cancer Pathobiology 75 85 94 18544963 10.1159/000123846 1:STN:280:DC%2BD1czns1yjug%3D%3D (Pubitemid 351820726)
38. L Melchor J Benitez 2008 An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes Carcinogenesis 29 1475 1482 18596026 10.1093/carcin/bgn157 1:CAS:528:DC%2BD1cXhtVSis7vK
39. Waddell N, Arnold J, Cocciardi S et al (2009) Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0653-1
40. O Fletcher RS Houlston 2010 Architecture of inherited susceptibility to common cancer Nat Rev Cancer 10 353 361 20414203 10.1038/nrc2840 1:CAS:528:DC%2BC3cXltV2ksLc%3D
41. A Meindl H Hellebrand C Wiek, et al. 2010 Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene Nat Genet 42 410 414 20400964 10.1038/ng.569 1:CAS:528:DC%2BC3cXkvVCjtbo%3D